Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) General Information

Description

GX301 is a clinical-stage therapeutic vaccine based in Torino, Italy. The vaccine is composed of multiple peptides and adjuvants and is designed to induce potent immune responses that are specific for cancer cells through the activation of both CD4+ and CD8+ T lymphocytes.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Turin
  • Italy
Primary Industry
Buildings and Property
Corporate Office
  • Turin
  • Italy

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)‘s full profile, request access.

Request a free trial

Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)‘s full profile, request access.

Request a free trial

Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) FAQs

  • Where is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) headquartered?

    Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) is headquartered in Turin, Italy.

  • What industry is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) in?

    Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)’s primary industry is Buildings and Property.

  • Is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) a private or public company?

    Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) is a Private company.

  • What is Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)’s current revenue?

    The current revenue for Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) is .

  • Who are Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)’s investors?

    Genovax has invested in Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin).

  • When was Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) acquired?

    Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) was acquired on 03-Dec-2012.

  • Who acquired Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin)?

    Genovax (GX301 A Clinical-Stage Therapeutic Vaccine in Turin) was acquired by Mediolanum Farmaceutici.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process